Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor–Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint

類似資料

• Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor–Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint
  著者:: Ettienne J. Myburgh, 等
  出版事項: (2017-08-01)
• Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test()
  著者:: Mittempergher, Lorenza, 等
  出版事項: (2020)
• Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor‐Positive, HER‐2 Negative Breast Cancer
  著者:: Van Asten, Kathleen, 等
  出版事項: (2018)
• Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer
  著者:: Zhao, Shen, 等
  出版事項: (2019)
• The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
  著者:: Myburgh, Ettienne J., 等
  出版事項: (2021)